Skip to content

PVP Labs

About
Taphalgin
Arvidal
Dalardenol
Promising developments
Contacts

PVP Labs was a finalist in the WIPO-IPOS IP FOR INNOVATION AWARDS 2021 in Singapore

admin 11/13/2021 No comments

Post navigation

PVP Labs signs an MOU with FITT Akza Indonesia, and Swiss Pharma Can (www.swisspharmacan.ch/) for “Cooperation, Development and Research of Arvidal to Combat Covid-19”.

The TAPHALGIN and ARVIDAL Trademarks have been granted legal protection in more than 30 countries around the world.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.

Search for:

Recent Posts

2022 Phase 3 Clinical trials of Taphalgin for patients with chronic pain have been successfully completed.
Phase 3 Clinical trials of Taphalgin have commence for patients suffering with postoperative pain.
PVP Labs Group has been established in the UAE, to develop the market for PVP products in the Middle East, India, and Africa.
PVP Labs has established Taph Corporation in the United States, with the primary goal of further developing the market for Taphalagin in America. Taphalgin is PVP’s non-narcotic pain management drug; patented in the US and Canada.
PVP Labs discovers – a life-saving solution that can be used during the early phase of viral infections, to assist humanity in its’ struggle against the viral spread

Recent Comments

Archives

April 2022
March 2022
February 2022
December 2021
November 2021
April 2020
February 2020
December 2019
September 2019
July 2019

Categories

main

Meta

Log in
Entries feed
Comments feed
WordPress.org

[email protected]

20 COLLYER QUAY, #09-01, SINGAPORE, 049319

The Meydan Hotel, Grandstand, 6-th floor, Meydan Road, Nad Al Sheba, Dubai, UAE

+971 56 460 7964

©2016-2024 PVP LABS PTE.LTD

Secondary Menu